3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Prostatic Neoplasms
108
Lymphoma, Large B-Cell, Diffuse
97
Lymphoma
86
Precursor Cell Lymphoblastic Leukemia-Lymphoma
57
Lymphoma, Non-Hodgkin
37
Lymphoma, Follicular
37
Burkitt Lymphoma
36
Leukemia
31
Multiple Myeloma
29
Lymphoma, Mantle-Cell
26
Hodgkin Disease
25
Lymphoma, T-Cell, Peripheral
20
Lymphoma, Large-Cell, Immunoblastic
15
Lymphoma, Large-Cell, Anaplastic
15
Lymphoma, B-Cell, Marginal Zone
15
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
13
Neoplasm Metastasis
13
Lymphoma, B-Cell
13
Leukemia, Lymphocytic, Chronic, B-Cell
12
Recurrence
11
Neoplasms, Plasma Cell
11
Immunoblastic Lymphadenopathy
11
Lymphoma, T-Cell
8
Dendritic Cell Sarcoma, Interdigitating
8
Blast Crisis
8
Neoplasms
7
Enteropathy-Associated T-Cell Lymphoma
7
Waldenstrom Macroglobulinemia
5
Primary Myelofibrosis
5
Myasthenia Gravis
5
Interventions
cemiplimab
1
Transdermal Patch
1
Sirolimus
1
Prednisone
1
Everolimus
1
Doxorubicin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Cutaneous Squamous Cell Carcinoma
×
Prednisone
×
Clear all
NCT04339062
2025-04-23
CONTRAC
Dana-Farber Cancer Institute
Phase 1/2
Completed
12 enrolled
13 charts